Biotechnology company Amgen has issued an request for information for its media business, with the expectation of formally reviewing the account in 2017, according to people with knowledge of the matter.
WPP's MEC Global has worked with Amgen since 2003. Representatives from the agency declined to comment.
Amgen, which did not respond to inquiry for comments, reviews the media business every three years as part of its procurement process, according to people with knowledge of the matter.
It was not immediately clear whether an outside consultant was helping with the review. In 2003, Ad Age reported that Select Resources International supported the media review. Representatives from SRI did not respond to inquiry for comment about the current Amgen review.
In the third quarter of 2016, Amgen beat analyst expectations, reporting revenue of $5.8 million, up 2% from the same period in 2015. Total product sales in the third quarter were flat, including sales from Amgen's most profitable brand, Enbrel, a medicine used to treat diseases such as moderate to severe rheumatoid arthritis and psoriatic arthritis.
Last year, Amgen spent nearly $136 million on measured media in the U.S., according to Kantar Media.